- Subclinical hyperthyroidism: diagnostic criteria and principles of treatment. Review of European Thyroid Association guidelines «Diagnosis and Treatment of endogenous subclinical hyperthyroidism», 2015
Subclinical hyperthyroidism: diagnostic criteria and principles of treatment. Review of European Thyroid Association guidelines «Diagnosis and Treatment of endogenous subclinical hyperthyroidism», 2015
HEALTH OF WOMAN. 2018.5(131):48–52
Galitskaya V. V.
Medical laboratory «Synevo»
This article presents the European Thyroid Association guidelines for diagnosis and treatment of subclinical hyperthyroidism, 2015. Determination of thyroid-stimulating hormone levels can help to diagnose a variety of pathological conditions: hypertension, cardiac fibrillation, atrial fibrillation, mineral density reduction in bones, menstrual irregularities, infertility, which require specific treatment after detection of hormonal status disorders (subclinical, overt), taking into account the patient’s age.
Diagnosis of endogenous subclinical hyperthyroidism is based solely on the results of laboratory tests, not clinical criteria. Endogenous subclinical hyperthyroidism is defined by the presence of sub-normal levels of thyroid-stimulating hormone with normal levels of free thyroxine, total triiodothyronine, and/or free triiodothyronine. There are two categories of endogenous subclinical hyperthyroidism: stage 1 – the level of thyroid-stimulating hormone is 0.1–0.39 mIU/l; stage 2 – the level of thyroid-stimulating hormone is <0.1 mIU/l. The levels of free thyroxine and free triiodothyronine, as a rule, are medium-high value at a subclinical level of thyroid hormone and can help differentiate between endogenous subclinical hyperthyroidism from overt hyperthyroidism.
It is recommended to study the thyroid-stimulating hormone level as the first test for the diagnosis of subclinical hyperthyroidism. In identifying low levels of thyroid-stimulating hormone it is necessary to investigate the level of free thyroxine, free or bound triiodothyronine.
Patients with primary sub-normal levels of thyroid-stimulating hormone with concentration of thyroid hormones in the upper limit or in normal range should be evaluated within 2-3 months.
It is recommended to perform scintigraphy and possible 24-hour test the absorption of radioactive iodine if in patient with 2nd degree endogenous subclinical hyperthyroidism there is nodular goiter to determine treatment strategy.
Ultrasonography with color Doppler can be informative for patients with endogenous subclinical hyperthyroidism and nodular goiter.
Determining the level of antibodies to thyroid-stimulating hormone receptors can confirm the etiology of autoimmune-induced hyperthyroidism.
Key words: thyroid, thyroid stimulating hormone, hyperthyroidism, thyrotoxicosis, subclinical hyperthyroidism, Graves’ disease, toxic multinodular goiter.
1. Biondi В, Bartalena L, Cooper DS et al. 2015. The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. Eur Thyroid J 4:149–163 https://doi.org/10.1159/000438750.
2. Surks MI, Ortiz E, Daniels GH et al. 2004. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA 291:228–238. https://doi.org/10.1001/jama.291.2.228; PMid:14722150
3. Biondi B, Palmieri EA, Klain M, Schlumberger M, Filetti S, Lombardi G. 2005. Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol 152:1–9. https://doi.org/10.1530/eje.1.01809; PMid:15762182https://doi.org/10.1530/eje.1.01809; PMid:15762182
4. Biondi B, Cooper DS. 2008. The clinical significance of subclinical thyroid dysfunction. Endocr Rev 29:76–131. https://doi.org/10.1210/er.2006-0043; PMid:17991805
5. Bahn RS, Burch HB, Cooper DS et al. 2011. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21:593–646. https://doi.org/10.1089/thy.2010.0417; PMid:21510801
6. Cooper DS, Biondi B. 2012. Subclinical thyroid disease. Lancet 379:1142–1154. https://doi.org/10.1016/S0140-6736(11)60276-6
7. Mitchell AL, Pearce SH. 2010. How should we treat patients with low serum thyrotropin concentrations? Clin Endocrinol (Oxf) 72:292–296. https://doi.org/10.1111/j.1365-2265.2009.03694.x; PMid:19744106
8. Bülow Pedersen I, Knudsen N, Jшrgensen T, Perrild H, Ovesen L, Laurberg P. 2002. Large differences in incidences of overt hyper- and hypothyroidism associated with a small difference in iodine intake: a prospective comparative register-based population survey. J Clin Endocrinol Metab 87:4462–4469. https://doi.org/10.1210/jc.2002-020750; PMid:12364419
9. Marqusee E, Haden ST, Utiger RD. 1998. Subclinical thyrotoxicosis. Endocrinol Metab Clin North Am 27:37–49. https://doi.org/10.1016/S0889-8529(05)70296-6
10. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC. 2000. The Colorado thyroid disease prevalence study. Arch Intern Med 160:526–534. https://doi.org/10.1001/archinte.160.4.526; PMid:10695693
11. Hollowell JG, Staehling NW, Flanders WD et al. 2002. Serum TSH, T(4), and thyroid antibodies in the United States population (1988–1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 87:489–499. https://doi.org/10.1210/jcem.87.2.8182; PMid:11836274
12. Aghini-Lombardi F, Antonangeli L, Martino E et al. 1999. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab 84:561–566. https://doi.org/10.1210/jc.84.2.561; https://doi.org/10.1210/jcem.84.2.5508; PMid:10022416
13. Paschke R, Hegedьs L, Alexander E, Valcavi R, Papini E, Gharib H. 2011. Thyroid nodule guidelines: agreement, disagreement and need for future research. Nat Rev Endocrinol. 7::354–361. https://doi.org/10.1038/nrendo.2011.1; PMid:21364517
14. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA, Stockigt JR. 2003. Guidelines Committee, National Academy of Clinical Biochemistry: Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 13:3–126. https://doi.org/10.1089/105072503321086962; PMid:12625976
15. Figge J, Leinung M, Goodman AD, Izquierdo R, Mydosh T, Gates S, Line B, Lee DW. 1994. The clinical evaluation of patients with subclinical hyperthyroidism and free triiodothyronine (free T 3) toxicosis. Am J Med 96:229–234. https://doi.org/10.1016/0002-9343(94)90147-3
16. Cooper DS, Laurberg P. 2013. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol 1:238–249. https://doi.org/10.1016/S2213-8587(13)70086-X
17. Harman SM, Wehmann RE, Blackman MR. 1984. Pituitary-thyroid hormone economy in healthy aging men: basal indices of thyroid function and thyrotropin responses to constant infusions of thyrotropin releasing hormone. J Clin Endocrinol Metab 58:320–326. https://doi.org/10.1210/jcem-58-2-320; PMid:6420436
18. Mariotti S, Franceschi C, Cossarizza A, Pinchera A. 1995. The aging thyroid. Endocr Rev 16:686–715. https://doi.org/10.1210/edrv-16-6-686; PMid:8747831
19. Surks MI, Boucai L. 2010. Age- and race-based serum thyrotropin reference limits. J Clin Endocrinol Metab 95:496–502. https://doi.org/10.1210/jc.2009-1845; PMid:19965925
20. Magri F, Muzzoni B, Cravello L, Fioravanti M, Busconi L, Camozzi D, Vignati G, Ferrari E. 2002. Thyroid function in physiological aging and in centenarians: possible relationships with some nutritional markers. Metabolism 51:105–109. https://doi.org/10.1053/meta.2002.28968; PMid:11782880
21. Mariotti S, Barbesino G, Caturegli P, Bartalena L, Sansoni P, Fagnoni F, Monti D, Fagiolo U, Franceschi C, Pinchera A. 1993. Complex alteration of thyroid function in healthy centenarians. J Clin Endocrinol Metab 77:1130–1134. . https://doi.org/10.1210/jc.77.5.1130; https://doi.org/10.1210/jcem.77.5.8077303; PMid:8077303
22. Belin RM, Astor BC, Powe NR, Ladenson PW. 2004. Smoke exposure is associated with a lower prevalence of serum thyroid autoantibodies and thyrotropin concentration elevation and a higher prevalence of mild thyrotropin concentration suppression in the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab 89:6077–6086. https://doi.org/10.1210/jc.2004-0431; PMid:15579761
23. Diana T, Kanitz M, Lehmann M, Li Y, Olivo PD, Kahaly GJ. 2015. Standardization of a bioassay for thyrotropin receptor stimulating autoantibodies. Thyroid 25:169–175. https://doi.org/10.1089/thy.2014.0346; PMid:25317659
24. Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P. 2001. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves’ disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol (Oxf) 55:381–390. https://doi.org/10.1046/j.1365-2265.2001.01347.x